source
- Acadia’s Alzheimer’s psychosis drug misses Phase 2 goals, but moves to revised Phase 3Acadia Pharmaceuticals announced that its experimental treatment for psychosis linked to Alzheimer’s disease failed to meet the primary endpoints in a Phase 2 trial. The company said the data stil…
- Merck's $1.3B EyeBio investment yields first ophthalmology successMerck's strategic move to re-enter ophthalmology has begun to show results after its 2024 acquisition of EyeBio. The company committed $1.3 billion upfront for EyeBio, aiming to broaden its pipeli…